InvestorsHub Logo
Followers 10
Posts 1104
Boards Moderated 0
Alias Born 12/07/2012

Re: doogdilinger post# 34547

Thursday, 04/26/2018 2:20:55 PM

Thursday, April 26, 2018 2:20:55 PM

Post# of 38634
Try try again.


From PAR's q4 2017

Revenues of $499 million, a 43 percent decrease compared to fourth-quarter 2016; this decline was primarily attributable to the loss of marketing exclusivity in the first half of 2017 for the first-to-file products ezetimibe tablets and quetiapine ER tablets. Also contributing to the decline were

The U.S. Generics Base business revenues decreased 37 percent compared to fourth-quarter 2016; this decrease primarily resulted from the impact of 2016 and 2017 competitive events, previously announced product discontinuances and the continued impact of pricing due to consolidation among our trade accounts.

They're getting hammered too in US generics.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent IPCI News